IMMUNOTHERAPY

Robert Jotte, MD, PhD, discussed findings from the phase 3 KRYSTAL-12 study evaluating adagrasib vs docetaxel in previously treated KRAS G12C-mutated non–small cell lung cancer.

Ajaz M. Khan, MD, MBA, CPE, provides his insights into the novel biomarkers and up-front immunotherapies that are changing the landscape of treatment for patients with lung cancer.

The SKYSCRAPER-06 trial for the first-line treatment of non–small cell lung cancer was stopped because the combination of tiragolumab and atezolizumab did not improve survival compared with the control of pembrolizumab and chemotherapy.

Neil Segal, MD, discussed findings from a phase 1/2 trial investigating REGN7075 in patients with solid tumors refractory to immunotherapy.

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.

A decision on the supplemental new drug application of osimertinib in this population is expected in the fourth quarter of 2024.

Alexa Simon Meara, MD, discussed how rheumatology and oncology can work together to improve outcomes for patients undergoing immunotherapy treatment for cancer.

If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.

A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.

The phase 1 study of HEMO-CAR-T in patients with acute myeloid leukemia can proceed following the lifted clinical hold.

In an interview with Targeted Oncology, Mark Dybul, MD, discussed a breakthrough method of immunotherapy in solid tumors.

In an interview with Targeted Oncology, Guenther Koehne, MD, provides a comprehensive overview of the dynamic landscape and evolving strategies in immunotherapy for hematologic malignancies.

Findings from a phase 2 study found that treatment with axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma led to a complete metabolic response of 71%.

A retrospective study of the CATCH-IT database provided data on patients with HIV who received immunotherapy for multiple cancer types, demonstrating safety and efficacy in most cases.

The FDA approves of the phase 3 IOV-LUN-202 study design, which will include approximately 120 patients with post-anti-PD-1 non–small cell lung cancer to be treated with LN-145.

The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.

The speed at which immunotherapy is adopted by oncology practices depends on their size, location, and affiliation, according to an analysis.

In an interview with Targeted Oncology, Bruno Bockorny, MD, discussed background and key takeaways from the phase 1 C-800 study.

In an interview with Targeted Oncology, Nitika Sharma, MD, discussed frontline treatment options for small cell lung cancer and data supporting their use. Sharma also discussed ongoing clinical trials that may bring new therapies in the near future.

YB-200, an investigational CEACAM antibody, has caught the attend of the FDA.

In an interview with Targeted Oncology, Patrick Wen, MD, discussed precision medicine for adult gliomas, including present and future treatment options.

In an interview with Targeted Oncology, John Diaz, MD summarized the ovarian cancer treatment paradigm, and discussed the role of genomic testing and novel targets being explored in the space.

Manmeet Ahluwalia, MD, discusses the purpose behind the Inaugural Miami Cancer Institute Precision Oncology Symposium.

In an interview with Targeted Oncology™, Manmeet Ahluwalia, MD, discussed the importance of the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium, what to expect from his presentation on brain metastases, and what to expect from presentations by other experts.

An investigational immunotherapy triplet combination is showing promise for the treatment of advanced solid tumors. Recruitment for the phase 2 study continues.

According to Benjamin P. Levy, MD, clinicians can use the information currently available to best decide the treatment sequence of immunotherapy vs targeted agents in locally advanced non–small cell lung cancer.

Refining current regimens and other emerging approaches will be delineated in melanoma, according to Omid Hamid, MD.

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed 3-year data on overall survival and subgroup analysis for the CheckMate 9LA trial of ipilimumab, nivolumab, and 2 cycles of chemotherapy.

A first-in-human study investigating the safety and immunogenicity of amplivant adjuvant and human papillomavirus type 16 synthetic long peptides demonstrated highly favorable safety and tolerability when used as an intradermal therapeutic vaccine.